Vaccines - Market Insights, Competitive Landscape, and Market Forecast - 2030

Vaccines Market By Type (Inactivated Vaccines, Live-Attenuated Vaccines, Subunit Vaccines, Recombinant Vaccines, Messenger Rna Vaccines, Toxoid Vaccines, Viral Vector Vaccines, And Combination Vaccines), By Indication (Cancer, Viral, And Bacterial), By Age Group (Adults And Pediatrics), By End-User (Hospitals, Clinics, And Vaccination Centers), and by geography is expected to advance at a respectable CAGR forecast till 2030 owing to extensive focus on child immunization programs and increasing incidence of infectious diseases.

The global vaccines market will grow at a CAGR of -11.47% during the forecast period from 2024 to 2030 to reach USD 65,074.86 million by 2030. The vaccines market is witnessing positive market growth owing to the factors such as the rising prevalence of cancers such as liver, cervical, and others that are contributing to the growing demand for therapeutics as well as prophylactic cancer vaccines. Moreover, the growing focus on reducing childhood morbidity and mortality rates due to preventable diseases in children is another prominent factor responsible for the growth of the vaccine market. Additionally, the COVID-19 pandemic also presented opportunities for growth for the vaccines market across the globe as it created an exigency for the COVID-19 vaccines.

Vaccines Market Dynamics:

One of the key aspects driving the vaccine market can be attributed to the surge in the prevalence of infectious diseases such as tuberculosis, typhoid, influenza, diphtheria, and others.

The rising tuberculosis cases worldwide are a potent market driver for the vaccine. According to World Health Organization 2022, around 10 million people worldwide have tuberculosis, including 5.6 million men, 3.3 million women, and 1.1 million children in 2020, thus increasing the demand for Bacillus Calmette-Guerin (BCG) vaccine for protection against tuberculosis.

Moreover, the WHO (2023) estimated that 1.5 million children under the age of 5 lose their lives to vaccine-preventable diseases every year across the globe. Immunization can prevent the suffering and death associated with infectious diseases like polio, measles, and pneumonia. The WHO factsheet (2023) further stated that immunization currently prevents 3.5-5 million deaths every year from diseases like diphtheria, tetanus, pertussis, influenza, and measles. Thus, the growing need for vaccines in preventing morbidity and mortality associated with infectious diseases in the pediatric as well as the adult population is expected to drive the global demand for vaccines ultimately boosting the growth of the global vaccines market.

In another example, the COVID-19 infection caused by the novel coronavirus quickly became a global threat by the end of 2019. As per the data provided by the WHO, as of 16 August 2022, there have been 588,757,628 confirmed cases of COVID-19, including 6,433,794 deaths. Additionally, the development of COVID-19 vaccines has been a prominent factor in providing immunity to people against the SARS-CoV-2 virus.

One of the key aspects driving the vaccine market can be attributed to the surge in cancer incidence. The GLOBOCAN study conducted by the International Agency for Research on Cancer mentioned that in 2020, an estimated number of 19.3 million new cancer cases (18.1 million excluding non-melanoma skin cancer) and approximately 10.0 million cancer deaths were reported globally. The source mentioned above also stated that in 2020, lung cancer was the main cause accounting for the highest number (1.8 million) of cancer-related deaths followed by colorectal (9.4%), liver (8.3%), stomach (7.7%), and female breast (6.9%) cancers. Cancer, being a debilitating disease, requires extensive treatment to treat cancerous cells. Cancer vaccines help protect against cancers caused by viruses in both preventive and therapeutic ways. Thus, the growing need for cancer vaccines which can be attributed to the increasing cancer incidence may result in the growing demand for cancer vaccines. Considering the efficacy of cancer vaccines in cancer treatment, there is a robust cancer vaccine pipeline which may result in more products gaining regulatory approval in coming years. Therefore, all the aforementioned factors are projected to contribute to the growing demand for cancer vaccines ultimately driving the growth of the global vaccines market.

However, vaccine hesitancy in a certain section of people and stringent government regulations for product approval may prove to be challenging factors for vaccine market growth.

The vaccines market was slightly impacted during the initial stages of the COVID-19 pandemic owing to the implementation of measures to curb the spread of the COVID-19 infection. For instance, the pandemic disrupted the immunization programs run by various international organizations such as the United Nations Children's Fund (UNICEF), Pan American Health Organization (PAHO), and WHO among other organizations. For instance, as reported by UNICEF, in May 2020, 99 countries reported the termination of the immunization campaigns for various infectious diseases including polio, diphtheria-tetanus-pertussis (DTP), and measles/rubella among others. This presented a massive decrease in the uptake of vaccines across the globe. However, on the other hand, prominent key biopharmaceutical companies such as Bharat Biotech, AstraZeneca, Pfizer Inc., Moderna, and Johnson & Johnson, among others, were conducting robust research and development activities to release the COVID-19 vaccine as soon as possible so that causalities can be reduced to a minimum. Nevertheless, the market for vaccines is on a period of recovery owing to the development and approval of various COVID-19 vaccines including Oxford-AstraZeneca COVID-19 vaccine (COVISHIELD(TM) and Vaxzevria), Pfizer-BioNTech COVID-19 Vaccine (COMIRNATY®), and Bharat Biotech's COVAXIN® among others and resumption of the regular immunization programs across the globe thereby presenting a positive future outlook for vaccines market during the forecast period from 2024-2030.

Vaccines Market Segment Analysis:

Vaccines Market by Type (Inactivated Vaccines, Live-Attenuated Vaccines, Subunit Vaccines, Recombinant Vaccines, Messenger RNA Vaccines, Toxoid Vaccines, Viral Vector Vaccines, and Combination Vaccines), Indication (Cancers, Viral, and Bacterial), Age Group (Adults and Pediatrics), End-Users (Hospitals, Clinics, and Vaccination Centers), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the indication segment of the vaccines market, the viral category is estimated to grow at a CAGR of -21.78% during the forecast period from 2024 to 2030 to reach USD 28,049.99 million by 2030. This can be attributed to the huge prevalence of multiple viral diseases including COVID- 19, influenza, Hepatitis B, and others globally which further increases the demand for vaccines against these.

As per the data published by the World Health Organization 2022, globally, around 296 million people were living with chronic Hepatitis B in 2019, and about 1.5 million new infections are recorded yearly. Younger children are highly recommended by WHO to get the Hepatitis B vaccine that protects them for 20 years or lifelong. For example, ENGERIX-B developed by GlaxoSmithKline Biologicals is a type of recombinant vaccine that is indicated for immunization against infection caused by all known subtypes of hepatitis B virus.

Rabies which occurs after the transmission of the virus from dogs is a fatal but vaccine-preventable disease. According to World Health Organization 2022, more than 29 million people worldwide received a post-bite rabies vaccination. Also, as per the same source, globally, the total economic burden of dog-mediated rabies annually is estimated at USD 8.6 billion. Rabies vaccine such as IMOVAX that is developed by Sanofi Pasteur, SA is indicated for pre-exposure and post-exposure prophylaxis against rabies in all age groups.

Vaccines against viral diseases are highly recommended by various prominent organizations such as the Centers for Disease Prevention and Control (CDC), World Health Organization (WHO), and the United Nations (UN). These vaccines are essential in reducing disease transmission, such as in the case of COVID-19, and others, along with boosting immunity against multiple viral diseases and assisting in viral disease eradication such as in the case of smallpox and polio which were highly prevalent in earlier times.

Therefore, owing to the prevalence of viral diseases and their tendency to turn into a global pandemic, the viral category is expected to witness considerable growth eventually contributing to the overall growth of the global vaccines market during the forecast period.

North America is expected to dominate the overall Vaccines Market:

Among all the regions, North America dominated the market and is estimated to grow at a CAGR of -11.57% during the forecast period from 2024 to 2030 to reach USD 29,446.24 million by 2030. This can be ascribed to the increasing prevalence of cancers, and extensive vaccination programs being conducted in the region, particularly in the United States. Furthermore, high disposable income, sophisticated healthcare infrastructure, and an extensive focus on therapy development are other factors that act as a supportive factor for North America vaccine market growth.

One of the key supporting factors for the growth of the North America vaccines market is the increasing prevalence of cancers in the United States. As per the figures mentioned by the American Cancer Society, in 2022, it was estimated that 1.9 million new cancer cases have been diagnosed in the United States. The data provided by the Centers for Disease Control and Prevention (2023), around 1,752,735 new cases of cancers were reported in the US in 2019. Also, as per the estimates of the American Cancer Society 2022, approximately 14,100 new cases of invasive cervical cancer will be reported and near about 4,280 women are expected to die from cervical cancer in 2022. Considering the high incidence of cancers, the demand for cancer vaccines is set to increase in the country. This is further evident from the ongoing extensive research in the development of cancer vaccines such as based on mRNA which may open up another avenue for the approval of such vaccines subsequently driving the growth of the vaccines market in the United States.

Another aspect stimulating the growth of the United States vaccines market is the extensive vaccination programs being run in the country. For instance, the Advisory Committee on Immunization Practices (ACIP) issues guidelines specific to vaccination in the country. Additionally, the Centers for Disease Control and Prevention (CDC) distributes >75 million doses of vaccines from most vaccine manufacturers to vaccine administration sites participating in the Vaccines for Children (VFC) program across the country, including health departments and private health providers, to be administered to VFC-eligible children. Moreover, the growing focus on developing COVID-19 vaccines has also been a key factor in driving the demand for vaccines in the United States. To ensure optimum distribution of COVID-19 vaccines in the country, several programs such as the Federal Retail Pharmacy Program, and the Health Center COVID-19 Vaccine Program are being run in the country to provide access to COVID-19 vaccines across the country. Therefore, the increasing focus on running vaccination programs in the country for various diseases is expected to contribute to the growth of the vaccine market in the United States. Thus, propelling the growth of the North America region market.

Vaccines Market Key Players:

Some of the key market players operating in the vaccines market include GlaxoSmithKline, Bharat Biotech, AstraZeneca, Bavarian Nordic A/S, BioNTech, Sanofi, Merck & Co., Inc, Pfizer Inc, Moderna, Meiji Holdings Co., Ltd., EMERGENT, CSL Limited, Johnson & Johnson, VBI Vaccines Inc., Valneva SE., Novavax, CanSinoBIO, Biokangtai, Dynavax Technologies, Zhi Fei Biological, and others.

Recent Developmental Activities in the Vaccines Market:

In February 2022, the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom granted regulatory approval to Novavax for their COVID-19 vaccine Nuvaxovid.

In October 2022, the World Health Organization announced the recommendation of the first malaria vaccine for children- Mosquirix, which was considered a breakthrough by the U.N. agency as a "historic moment."

In October 2022, Seqirus received regulatory approval from the U.S. Food and Drug Administration (FDA) for their FLUCELVAX® QUADRIVALENT (Influenza Vaccine), which is the company's cell-based quadrivalent influenza vaccine, for an expanded age indication for children as young as six months old.

Key Takeaways from the Vaccines Market Report Study

• Market size analysis for current vaccines market size (2023), and market forecast for 5 years (2024-2030)
• The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the vaccine market.
• Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years
• Key companies dominating the global vaccines market.
• Various opportunities available for the other competitor in the vaccines market space.
• What are the top-performing segments in 2023? How these segments will perform in 2030.
• Which are the top-performing regions and countries in the current vaccines market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for vaccine market growth in the coming future?

Target Audience who can be benefited from this Vaccine Market Report Study

• Vaccine providers
• Research organizations and consulting companies
• Vaccine-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and Traders dealing in vaccines
• Various end users who want to know more about the vaccines market and the latest technological developments in the vaccines market.

Frequently Asked Questions for Vaccines Market:

1. What are vaccines?

Vaccines are preparations that contain a weakened or killed form of pathogen or their part or any other form such that it is no longer virulent (ability to cause disease) to imbibe active immunity in a person in which it is administered by triggering the adaptive immune response.

2. What is the global market for Vaccines?

The global vaccines market will grow at a CAGR of -11.47% during the forecast period from 2024 to 2030 to reach USD 65,074.86 million by 2030.

3. What are the drivers for Global Vaccines Market?

The vaccines market is witnessing positive market growth owing to the factors such as the rising prevalence of cancers that are contributing to the growing demand for therapeutics as well as prophylactic cancer vaccines. Moreover, the growing focus on reducing childhood morbidity and mortality rates due to preventable diseases in children is another prominent factor responsible for the growth of the vaccine market. Additionally, the COVID-19 pandemic also presented opportunities for growth for the vaccines market across the globe as it created an exigency for the COVID-19 vaccines.

4. Who are the key players operating in Global Vaccines Market?

Some of the key market players operating in the vaccines market include GlaxoSmithKline, Bharat Biotech, AstraZeneca, Bavarian Nordic A/S, BioNTech, Sanofi, Merck & Co., Inc, Pfizer Inc, Moderna, Meiji Holdings Co., Ltd., EMERGENT, CSL Limited, Johnson & Johnson, VBI Vaccines Inc., Valneva SE., Novavax, CanSinoBIO, Biokangtai, Dynavax Technologies, Zhi Fei Biological, and others.

5. Which region has the highest share in Vaccines Market?

Among all the regions, North America is estimated to amass a significant revenue share in the global vaccines market. This can be ascribed to the increasing prevalence of cancer, and extensive vaccination programs being conducted in the region, particularly in the United States. Furthermore, high disposable income, sophisticated healthcare infrastructure, and an extensive focus on therapy development are other factors that act as a supportive factors for North America vaccine market growth.